Life Science Compliance Update



It’s Not Just Money – Theranos & SEC Come to Terms

Written by , Posted in Uncategorized

Robert N. Wilkey, Esq., Staff Writer for Life Science Compliance Update

On March 14, 2018, the SEC charged Theranos and two of its executives in Silicon Valley with raising more than $700 million from investors through a fraud in which they exaggerated or made false statements about the company’s technology, business, and financial performance. Even though Theranos was a private company, the SEC settlement stands as a cautionary tale to those life science companies seeking financing.


Topic tags:

Menu Title